Detalles de la búsqueda
1.
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Br J Cancer
; 128(12): 2227-2235, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37087488
2.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med
; 383(23): 2207-2218, 2020 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33264544
3.
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Cancer Immunol Immunother
; 72(7): 2443-2458, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37016126
4.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34784056
5.
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Oncologist
; 27(11): 905-e848, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36156099
6.
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer
; 149(2): 403-408, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33709428
7.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33336844
8.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33660194
9.
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 39(1): 163-174, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32737717
10.
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Invest New Drugs
; 39(1): 182-192, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910338
11.
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
JAMA
; 325(13): 1277-1286, 2021 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33821899
12.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653053
13.
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours.
Br J Cancer
; 123(8): 1235-1243, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32741971
14.
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Oncologist
; 25(11): 954-962, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32812320
15.
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Oncologist
; 25(3): e451-e459, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162804
16.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707688
17.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 419-432, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31020608
18.
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
BMC Cancer
; 20(1): 633, 2020 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32641104
19.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 20(6): 849-861, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31003911
20.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Lancet Oncol
; 20(8): 1109-1123, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31301962